Marken to add Kenya and Ghana to GMP storage network

By Jane Byrne

- Last updated on GMT

© GettyImages/John M Lund Photography Inc
© GettyImages/John M Lund Photography Inc

Related tags Cold chain Kenya Marken cell and gene therapy

Marken, the clinical trial logistics subsidiary of UPS Healthcare, is adding significant capacity to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials.

It has expanded its cold chain services and packaging solutions, whle new storage locations in Kenya and Ghana are in the pipeline. The idea is to provide increased flexibility and global access for customers, including in emerging markets like South Korea and Sub-Saharan Africa.

The UPS subsidiary sees the investments as especially critical for cell and gene therapy (CGT) developers, where there is increased innovation enabled by mRNA, CAR-T, and viral vectors. and huge growth forecast for that segment. The US Food and Drug Administration (FDA) is expected to approve 10 to 20 CGT products per year by 2025.  

Ariette van Strien, president of Marken, told BioPharma-Reporter: “Expanding our GMP network, including cold chain, is critical for cell and gene therapy developers as it allows them to reach patients in previously unreached populations. We’re excited about our planned expansion into Ghana and Kenya as it can help with temporary and permanent storage of mRNA vaccines or even cell and gene therapies to these regions.”

Marken’s ongoing and planned investments include:

  • The addition of over 100,000 square feet of GMP-compliant depot operations in Louisville, KY, Great Valley, PA, and Seoul, South Korea.
  • A new GMP depot facility in Kiev, Ukraine.
  • A new GDP depot facility in Osaka, Japan.
  • New locations in Nairobi, Kenya and Accra, Ghana.
  • Expansion of its kit assembly facility in Shanghai, China.
  • New liquid nitrogen (LN2) filling stations within each of its global cell and gene centers of excellence.
  • Infrastructure expansion at its facilities in Belgium, France, South Africa, India, Taiwan, China, and Singapore.
  • Packaging and technology enhancements for real-time location tracking and temperature monitoring of cell and gene therapy shipments.

In addition to GMP storage, the company will be able to track cell and gene therapy, compassionate use, and early access program shipments from its Ukraine facility.

“This new control center, combined with the existing control center in Durham, NC, US, will enhance 24/7/365 global monitoring of all complex shipments, including cell and gene shipments.”

Related news

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more